Product Description
Lofexidine is used to manage opioid withdrawal symptoms (e.g., sick feeling, stomach cramps, muscle spasms or twitching, cold sensation, heart pounding, muscle tension, aches and pains, yawning, runny eyes, or difficulty falling asleep or staying asleep) that may occur after an opioid medication is suddenly stopped. Lofexidine is in a class of medications called central alpha adrenergic agonists. It works by relaxing blood vessels so that blood can flow more easily through the body. (Sourced from: https://medlineplus.gov/druginfo/meds/a618036.html)
Mechanisms of Action: ADRA2A Agonist,ADRA2B Agonist,ADRA2C Agonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Approved
Approved Countries: Egypt | Ireland | New Zealand | United Kingdom | United States
Approved Indications: None
Known Adverse Events: None
Company: USWM
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: United States
Active Clinical Trial Count: 3
Highest Development Phases
Phase 2: Opioid-Related Disorders|Stress Disorders, Post-Traumatic|Substance Withdrawal Syndrome
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| USWM-LX1-1014 | P1 |
Not yet recruiting |
Opioid-Related Disorders|Substance Withdrawal Syndrome |
2026-01-01 |
|
| AS170014-A6 | P2 |
Recruiting |
Stress Disorders, Post-Traumatic|Opioid-Related Disorders |
2025-06-30 |
|
| USWM-LX2-2001 | P2 |
Recruiting |
Substance Withdrawal Syndrome |
2024-12-01 |